We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Destiny Pharma Plc | LSE:DEST | London | Ordinary Share | GB00BDHSP575 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.00 | 5.48% | 19.25 | 19.00 | 19.50 | 19.25 | 18.25 | 18.25 | 166,659 | 16:01:22 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -6.5M | -0.0683 | -2.82 | 18.34M |
From Apr 2023 to Apr 2024
TIDMDEST
RNS Number : 2856Z
Destiny Pharma PLC
12 May 2023
Destiny Pharma plc
("Destiny Pharma" or the "Company")
Grant of Share Options
Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that it has granted options over a total of 431,354 new ordinary shares of GBP0.01 each in the Company ("Options") (representing 0.45 per cent. of the Company's issued share capital) to certain employees of the Company, including the Directors and PDMR named below.
Hot Features
Premium
Name Position Deferred Total Options Ordinary Ordinary
Bonus Options held Shares Shares
Options held as a percentage held held as
issued post of issued a percentage
Under issue share of issued
2020 capital share
LTIP capital
Scheme*
Chief Executive
Neil Clark Officer 52,264 1,424,798 1.50% 117,033 0.12%
------------------ ------------- ------------- ----------------- ----------- --------------
Chief Financial
Shaun Claydon Officer 47,100 911,001 0.96% 24,286 0.03%
------------------ ------------- ------------- ----------------- ----------- --------------
William Chief Scientific
Love** Officer 43,313 959,549 1.01% 6,509,500 6.83%
------------------ ------------- ------------- ----------------- ----------- --------------
Chief Medical
Yuri Martina Officer 71,177 261,177 0.27% - -
------------------ ------------- ------------- ----------------- ----------- --------------
* granted in respect of bonuses due for the financial year ended 31 December 2022
**3,317,700 of these Ordinary Shares are held by William Love and 3,191,800 are held by Carol Love
The above options granted to the Directors and PDMR represent awards granted under the Destiny Pharma plc 2020 Long Term Incentive Plan approved by the Company on 22 December 2020 for EMI and non-tax advantaged options (the "Employee LTIP 2020"). The above options granted to the Directors and PDMR have been granted with a nominal exercise price, will vest on 1 February 2025 and are exercisable up to 10 years from the date of grant. Including the grant of these Options, the Company will have outstanding options over approximately 8.72 per cent. of its issued share capital.
For further information, please contact:
Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0)1273 704 440
pressoffice@destinypharma.com
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance
Alice Lane / Nigel Birks / Harriet Ward, ECM
+44 (0)20 7220 0500
Shore Capital (Joint Broker)
Daniel Bush / James Thomas / Lucy Bowden
+44 (0) 207 408 4090
Optimum Strategic Communications
Mary Clark / Nick Bastin / Manel Mateus / Eleanor Cooper
+44 (0) 203 922 0891
DestinyPharma@optimumcomms.com
MC Services AG
Anne Hennecke / Andreas Burckhardt
+49-211-529252-12
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has completed a positive Phase 2 clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV(TM) , a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF drug research projects.
For further information on the Company, please visit https://www.destinypharma.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Neil Clark
------------------------------- ------------------------------------
2. Reason for the Notification
---------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------- ------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------
a) Name Destiny Pharma plc
------------------------------- ------------------------------------
b) LEI 213800O9WH9Z38EHAC95
------------------------------- ------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
---------------------------------------------------------------------
a) Description of the Grant of award of options over
Financial instrument, ordinary shares of 1 pence each
type of instrument ("Ordinary Shares") under the
2020 Destiny Pharma plc Long
Term Incentive Plan.
Identification code DEST GB00BDHSP575
------------------------------- ------------------------------------
b) Nature of the transaction Grant of award of options over
Ordinary Shares under the 2020
Destiny Pharma plc Long Term
Incentive Plan.
------------------------------- ------------------------------------
c) Price(s) and volume(s) 1 pence exercise price per Ordinary
Share
52,264 Ordinary Shares
------------------------------- ------------------------------------
d) Aggregated information:
Aggregated volume See 4c) above
Price
------------------------------- ------------------------------------
e) Date of the transaction 12 May 2023
------------------------------- ------------------------------------
f) Place of the transaction Outside of trading venue
------------------------------- ------------------------------------
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Shaun Claydon
------------------------------- ------------------------------------
2. Reason for the Notification
---------------------------------------------------------------------
a) Position/status Chief Financial Officer
------------------------------- ------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------
a) Name Destiny Pharma plc
------------------------------- ------------------------------------
b) LEI 213800O9WH9Z38EHAC95
------------------------------- ------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
---------------------------------------------------------------------
a) Description of the Grant of award of options over
Financial instrument, ordinary shares of 1 pence each
type of instrument ("Ordinary Shares") under the
2020 Destiny Pharma plc Long
Term Incentive Plan.
Identification code DEST GB00BDHSP575
------------------------------- ------------------------------------
b) Nature of the transaction Grant of award of options over
Ordinary Shares under the 2020
Destiny Pharma plc Long Term
Incentive Plan.
------------------------------- ------------------------------------
c) Price(s) and volume(s) 1 pence exercise price per Ordinary
Share
47,100 Ordinary Shares
------------------------------- ------------------------------------
d) Aggregated information:
Aggregated volume See 4c) above
Price
------------------------------- ------------------------------------
e) Date of the transaction 12 May 2023
------------------------------- ------------------------------------
f) Place of the transaction Outside of trading venue
------------------------------- ------------------------------------
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name William Love
------------------------------- ------------------------------------
2. Reason for the Notification
---------------------------------------------------------------------
a) Position/status Chief Scientific Officer
------------------------------- ------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------
a) Name Destiny Pharma plc
------------------------------- ------------------------------------
b) LEI 213800O9WH9Z38EHAC95
------------------------------- ------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
---------------------------------------------------------------------
a) Description of the Grant of award of options over
Financial instrument, ordinary shares of 1 pence each
type of instrument ("Ordinary Shares") under the
2020 Destiny Pharma plc Long
Term Incentive Plan.
Identification code DEST GB00BDHSP575
------------------------------- ------------------------------------
b) Nature of the transaction Grant of award of options over
Ordinary Shares under the 2020
Destiny Pharma plc Long Term
Incentive Plan.
------------------------------- ------------------------------------
c) Price(s) and volume(s) 1 pence exercise price per Ordinary
Share
43,313 Ordinary Shares
------------------------------- ------------------------------------
d) Aggregated information:
Aggregated volume See 4c) above
Price
------------------------------- ------------------------------------
e) Date of the transaction 12 May 2023
------------------------------- ------------------------------------
f) Place of the transaction Outside of trading venue
------------------------------- ------------------------------------
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Yuri Martina
------------------------------- ------------------------------------
2. Reason for the Notification
---------------------------------------------------------------------
a) Position/status Chief Medical Officer
------------------------------- ------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------
a) Name Destiny Pharma plc
------------------------------- ------------------------------------
b) LEI 213800O9WH9Z38EHAC95
------------------------------- ------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
---------------------------------------------------------------------
a) Description of the Grant of award of options over
Financial instrument, ordinary shares of 1 pence each
type of instrument ("Ordinary Shares") the 2020
Destiny Pharma plc Long Term
Incentive Plan.
Identification code DEST GB00BDHSP575
------------------------------- ------------------------------------
b) Nature of the transaction Grant of award of options over
Ordinary Shares under the 2020
Destiny Pharma plc Long Term
Incentive Plan.
------------------------------- ------------------------------------
c) Price(s) and volume(s) 1 pence exercise price per Ordinary
Share
71,177 Ordinary Shares
------------------------------- ------------------------------------
d) Aggregated information:
Aggregated volume See 4c) above
Price
------------------------------- ------------------------------------
e) Date of the transaction 12 May 2023
------------------------------- ------------------------------------
f) Place of the transaction Outside of trading venue
------------------------------- ------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHATMBTMTTBBIJ
(END) Dow Jones Newswires
May 12, 2023 07:24 ET (11:24 GMT)
1 Year Destiny Pharma Chart |
1 Month Destiny Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
